Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
5.23
-0.09 (-1.69%)
Apr 6, 2026, 1:18 PM EDT - Market open
Sagimet Biosciences Employees
Sagimet Biosciences had 16 employees as of December 31, 2025. The number of employees increased by 2 or 14.29% compared to the previous year.
Employees
16
Change (1Y)
2
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$3,189,875
Market Cap
170.42M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 2 | 14.29% | 16 | 0 |
| Dec 31, 2024 | 14 | 4 | 40.00% | 14 | 0 |
| Dec 31, 2023 | 10 | 0 | - | 8 | 2 |
| Dec 31, 2022 | 10 | 3 | 42.86% | 9 | 1 |
| Dec 31, 2020 | 7 | - | - | 6 | 1 |
Related Stocks
Employee RankingsSGMT News
- 6 hours ago - Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 weeks ago - Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne - GlobeNewsWire
- 2 months ago - Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne - PRNewsWire
- 2 months ago - Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor - GlobeNewsWire
- 3 months ago - Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference - GlobeNewsWire